A generalist private equity firm was considering an investment in a computational chemistry company, and required an evaluation of the company’s software suite as part of its due diligence of the investment.
Alacrita deployed a medicinal chemist with a strong background in computational chemistry to conduct an extensive trial of the software using real world examples of ligand- and structure-based design, in comparison with the product offerings of key competitors. We complemented this by conducting interviews with key members of the company management team and reviewing product development plans to address the few gaps in product functionality. We concluded that the company was well-positioned in its industry with a competitive software platform.
Alacrita due diligence consultants have been a trusted DD source for close to fifteen years, conducting assignments for large pharma, biotech, universities and investors. Every due diligence we perform is underpinned by our ability to incorporate individuals into each project who have the exact matching expertise required for a complete, thorough and accurate assessment.